Histogen Announces 1-for-20 Reverse Stock Split
bdtonline.com
news
2022-06-01 20:02:41

SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's issued and outstanding common stock (the 'Reverse Stock Split'). The Reverse Stock Split will be effective at 4:01 p.m.
